Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00076323 · ClinicalTrials.gov registry record · NA
A Test to Predict the Hemolytic Potential of Drugs in G6PD Deficiency
A NA study, sponsored by Walter Reed Army Institute of Research (WRAIR).
- Completed
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT00076323 is a NA study that has completed, run by Walter Reed Army Institute of Research (WRAIR). The registered enrollment target is 14 participants.
The verdict
NCT00076323, a NA study, has completed, sponsored by Walter Reed Army Institute of Research (WRAIR).
- COMPLETED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study will evaluate a new and safe testing method for identifying medicines that can cause problems in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals. We are looking for volunteers with G6PD deficiency who would be willing to donate blood samples.
Interventions
- DRUG Primaquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2003-12 |
| Est. Completion | 2006-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00076323
The ClinicalTrials.gov registry entry for NCT00076323 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Walter Reed Army Institute of Research (WRAIR), which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Primaquine is the first listed.
NCT00076323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00076323 about?
NCT00076323 is a clinical study titled "A Test to Predict the Hemolytic Potential of Drugs in G6PD Deficiency". This study will evaluate a new and safe testing method for identifying medicines that can cause problems in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals. We are looking for volunteers with G6PD deficiency who would be willing to donate blood samples.
What is the current status of trial NCT00076323?
This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2003-12. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00076323?
The interventions under investigation include: Primaquine (DRUG).
Who is sponsoring clinical trial NCT00076323?
This trial is sponsored by Walter Reed Army Institute of Research (WRAIR), which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.